. 2012 Apr 26;1:11. doi: 10.1186/2162-3619-1-11

Table 1.

Clinical information of the eligible trials for the meta-analysis

Trial	No. of pts	Regimens (per arm)	No. of pts (Male)	CIK Regimens	Culture of CIK cell
Dong 2009 [24]	127	CIK (3 course)	41 (31)	1.0-2.0 × 10¹⁰per course	CM, IFN-γ, CD3McAb, IL-1a, IL-2

		CIK (6 course)	43 (32)

		Surgery only	43 (34)

Weng 2008 [20]	85	TACE + RFA + CIK	45 (31)	1.0-1.5 × 10¹⁰per course	CM, IFN-γ, CD3McAb, IL-1a, IL-2

		TACE + RFA	40 (29)

Zhao 2006 [21]	64	TACE + RFA	31 (29)	1.1-1.5 × 10¹⁰per course	CM, IFN-γ, CD3McAb, IL-1a, IL-2

		TACE + RFA + CIK	33 (30)

Pan 2010 [22]	83	TACE + RFA + CIK	42 (37)	> 1.0 × 10¹⁰per course	CM, IFN-γ, CD3McAb, IL-1a, IL-2

		TACE + RFA	41 (34)

Hao 2010 [19]	146	TACE	74 (64)	1.0-5.0 × 10¹⁰per course	SFM, IFN-γ, CD3McAb, IL-1a, IL-2

		TACE + CIK	72 (65)

Lu 2008 [25]	30	CIK	12 (UK)	1.6 × 10¹⁰per course	SFM, IFN-γ, CD3McAb, IL-1a, IL-2

		Surgery alone	18 (UK)

Zhang 2007 [16]	44	TACE	20 (UK)	8.0 × 10⁹per course	CM, IFN-γ, CD3McAb, IL-1a, IL-2

		TACE + CIK	24(UK)

Guo 2007 [17]	61	TACE	31 (UK)	1.0-1.2 × 10¹⁰per course	CM, IFN-γ, CD3McAb, IL-1a, IL-2

		TACE + CIK	30 (UK)

Zhang 2006 [27]	144	TACE	30 (UK)	1.0-1.2 × 10¹⁰per course	CM, IFN-γ, CD3McAb, IL-1a IL-2

		TACE + CIK	16 (UK)

		TACE + PEI	62 (UK)

		TACE + PEI + CIK	36 (UK)

Shi 2007 [28]	252	TACE	134 (UK)	1.0-1.2 × 10¹⁰per course	CM, IFN-γ, CD3McAb, IL-1a, IL-2

		TACE + PEI	80 (UK)

		TACE + CIK	38 (UK)

Hao 2006 [18]	67	TACE + CIK	21 (17)	1.0-5.0 × 10¹⁰per course	CM, IFN-γ, CD3McAb, IL-1a, IL-2

		TACE	46 (45)

Wan 2008 [23]	61	TACE + RFA	34 (23)	1.0 × 10¹⁰per course	CM, IFN-γ, CD3McAb, IL-1a, IL-2

		TACE + RFA + CIK	27 (18)

Yu 2009 [26]	50	TACE + CIK	25 (22)	1.0-1.2 × 10¹⁰per course	CM, IFN-γ, CD3McAb, IL-1a, IL-2

		Surgery alone	25 (23)

Note: UK unknown; pts patients; TACE transcatheter arterial chemoembolization; RFA radiofrequency ablation; PEI percutaneous ethanol injection; IL interleukin; IFN-γ Interferon-γ; CM complete medium; SFM Serum-free culture medium